Key Highlights
-
Cefpodoxime Proxetil sees strong uptake in pediatric and respiratory infection treatments, with consistent growth in oral suspension and tablet formulations.
-
Further tariffs and yuan appreciation are inflating import costs, while Chinese exporters maintain supply despite rising production expenses.
-
Steady freight rates offer logistical stability, but inventory depletion and cautious procurement are keeping prices firm.
Cefpodoxime Proxetil continues to be a first-line medication for the treatment of upper respiratory infections, otitis media, and urinary tract infections. There are more prescriptions in U.S. hospitals and clinics, particularly in pediatric markets, where oral suspensions continue to be popular. Retail pharmacy sales for Cefpodoxime Proxetil also increased because of infection season peaks and greater insurance coverage Growing awareness of antimicrobial stewardship also has contributed to more targeted use, stimulating demand for high-quality generics.
This repeated application generated a massive demand for Cefpodoxime Proxetil active pharmaceutical ingredients (APIs), which...
